| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4368 | 2018 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 2556 | 2018 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2412 | 2018 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2142 | 2018 |
| Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 2011 | 2018 |
| Machine learning identifies stemness features associated with oncogenic dedifferentiation TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ... Cell 173 (2), 338-354. e15, 2018 | 1559 | 2018 |
| Inhibition of the hedgehog pathway in advanced basal-cell carcinoma DD Von Hoff, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, ... New England Journal of Medicine 361 (12), 1164-1172, 2009 | 1345 | 2009 |
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ... Journal of Clinical Oncology 29 (34), 4548, 2011 | 1229 | 2011 |
| Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study GK Abou-Alfa, V Sahai, A Hollebecque, G Vaccaro, D Melisi, R Al-Rajabi, ... The Lancet Oncology 21 (5), 671-684, 2020 | 1171 | 2020 |
| Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas TA Knijnenburg, L Wang, MT Zimmermann, N Chambwe, GF Gao, ... Cell reports 23 (1), 239-254. e6, 2018 | 905 | 2018 |
| Genomic and functional approaches to understanding cancer aneuploidy AM Taylor, J Shih, G Ha, GF Gao, X Zhang, AC Berger, SE Schumacher, ... Cancer cell 33 (4), 676-689. e3, 2018 | 848 | 2018 |
| The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma CJ Ricketts, AA De Cubas, H Fan, CC Smith, M Lang, E Reznik, R Bowlby, ... Cell reports 23 (1), 313-326. e5, 2018 | 817 | 2018 |
| Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images J Saltz, R Gupta, L Hou, T Kurc, P Singh, V Nguyen, D Samaras, ... Cell reports 23 (1), 181-193. e7, 2018 | 813 | 2018 |
| Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors MS Beg, AJ Brenner, J Sachdev, M Borad, YK Kang, J Stoudemire, ... Investigational new drugs 35, 180-188, 2017 | 795 | 2017 |
| Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ... The Lancet Oncology 21 (6), 796-807, 2020 | 744 | 2020 |
| Pathogenic germline variants in 10,389 adult cancers K Huang, RJ Mashl, Y Wu, DI Ritter, J Wang, C Oh, M Paczkowska, ... Cell 173 (2), 355-370. e14, 2018 | 703 | 2018 |
| Comprehensive analysis of alternative splicing across tumors from 8,705 patients A Kahles, KV Lehmann, NC Toussaint, M Hüser, SG Stark, ... Cancer cell 34 (2), 211-224. e6, 2018 | 702 | 2018 |
| Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers DD Von Hoff, JJ Stephenson Jr, P Rosen, DM Loesch, MJ Borad, ... J Clin Oncol 28 (33), 4877-4883, 2010 | 673 | 2010 |
| Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ... Journal of Clinical Oncology 36 (3), 276, 2018 | 670 | 2018 |
| Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines K Ellrott, MH Bailey, G Saksena, KR Covington, C Kandoth, C Stewart, ... Cell systems 6 (3), 271-281. e7, 2018 | 637 | 2018 |
Daniel Von HoffChief Scientific Officer US Oncology, Chief Scientific Officer TGen, Distinguished Professor MayoVerified email at tgen.org
